{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:20:37Z","timestamp":1777936837518,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T00:00:00Z","timestamp":1445558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2016,6]]},"abstract":"\n Background:<\/jats:title>\n Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients.<\/jats:p>\n <\/jats:sec>\n \n Objectives:<\/jats:title>\n To describe clinical phenotypes associated with anti-MOG.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/1352458515614093","type":"journal-article","created":{"date-parts":[[2015,10,23]],"date-time":"2015-10-23T21:59:06Z","timestamp":1445637546000},"page":"964-968","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients"],"prefix":"10.1177","volume":"22","author":[{"given":"Sasitorn","family":"Siritho","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand\/Bumrungrad International Hospital, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas K","family":"Sato","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan\/Department of Neurology, Faculty of Medicine, University of Sao Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihiko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naraporn","family":"Prayoonwiwat","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,10,23]]},"reference":[{"key":"bibr1-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"bibr2-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1111\/j.1759-1961.2012.00030.x"},{"key":"bibr3-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70216-8"},{"key":"bibr4-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2014.03.001"},{"key":"bibr5-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826aac4e"},{"key":"bibr6-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000101"},{"key":"bibr7-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.5857"},{"key":"bibr8-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0224-x"},{"key":"bibr9-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.118"},{"key":"bibr10-1352458515614093","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2014-310206"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458515614093","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458515614093","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458515614093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:45:43Z","timestamp":1777693543000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458515614093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,23]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1177\/1352458515614093"],"URL":"https:\/\/doi.org\/10.1177\/1352458515614093","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,23]]}}}